NovoCure
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell NovoCure and other ETFs, options, and stocks.About NVCR
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division.
CEOAshley Cordova
CEOAshley Cordova
Employees1,488
Employees1,488
HeadquartersSt. Helier, Jersey
HeadquartersSt. Helier, Jersey
Founded2000
Founded2000
Employees1,488
Employees1,488
NVCR Key Statistics
Market cap1.33B
Market cap1.33B
Price-Earnings ratio-7.36
Price-Earnings ratio-7.36
Dividend yield—
Dividend yield—
Average volume1.99M
Average volume1.99M
High today$12.01
High today$12.01
Low today$11.15
Low today$11.15
Open price$11.15
Open price$11.15
Volume1.28M
Volume1.28M
52 Week high$34.13
52 Week high$34.13
52 Week low$10.70
52 Week low$10.70
Stock Snapshot
The current NovoCure(NVCR) stock price is $11.86, with a market capitalization of 1.33B. The stock trades at a price-to-earnings (P/E) ratio of -7.36.
As of 2025-11-12, NovoCure(NVCR) stock has fluctuated between $11.15 and $12.01. The current price stands at $11.86, placing the stock +6.4% above today's low and -1.2% off the high.
The NovoCure(NVCR)'s current trading volume is 1.28M, compared to an average daily volume of 1.99M.
In the last year, NovoCure(NVCR) shares hit a 52-week high of $34.13 and a 52-week low of $10.70.
In the last year, NovoCure(NVCR) shares hit a 52-week high of $34.13 and a 52-week low of $10.70.
Analyst ratings
63%
of 8 ratingsBuy
62.5%
Hold
37.5%
Sell
0%
People also own
Based on the portfolios of people who own NVCR. This list is generated using Robinhood data, and it’s not a recommendation.